Aytu Biopharma (AYTU) Net Income towards Common Stockholders (2010 - 2025)
Aytu Biopharma (AYTU) posted quarterly Net Income towards Common Stockholders of $62000.0 for Q2 2025, up 105.0% year-over-year from $30243.3 in Q2 2024, and up 14.81% quarter-over-quarter from $54000.0 in Q1 2025.
Aytu Biopharma (AYTU) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Aytu Biopharma (AYTU) has reported Net Income towards Common Stockholders for 16 consecutive years, with $62000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Net Income towards Common Stockholders rose 105.0% year-over-year to $62000.0; the TTM figure through Mar 2026 stood at $62000.0 (up 109.1% YoY), while the FY2025 annual figure was $620000.0, up 118.65% from the prior year.
- Net Income towards Common Stockholders advanced to $62000.0 in Q2 2025 per AYTU's latest filing, from $54000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $7.0 million in Q2 2022 and bottomed at -$53.3 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$7.3 million across 5 years, with a median of -$839000.0 in 2023.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders plunged 546.8% — and 2024, when it surged 158.89%.
- Aytu Biopharma's Net Income towards Common Stockholders stood at -$11.5 million in 2021, then jumped by 42.04% to -$6.7 million in 2022, then surged by 87.46% to -$839000.0 in 2023, then soared by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
- Business Quant data shows AYTU's Net Income towards Common Stockholders at $62000.0 in Q2 2025, $54000.0 in Q1 2025, and $123000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Aytu Biopharma | 24.86 Mn | -1.86 Mn | 7.60 Mn | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | -1.24 Mn |
| Mar 31, 2024 | -599,000.00 |
| Dec 31, 2023 | -839,000.00 |
| Sep 30, 2023 | -647,000.00 |
| Jun 30, 2023 | -2.46 Mn |
| Mar 31, 2023 | -7.20 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -701,000.00 |
| Jun 30, 2022 | 6.96 Mn |
| Mar 31, 2022 | -53.29 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -27.85 Mn |
| Jun 30, 2021 | -18.74 Mn |
| Dec 31, 2020 | -9.53 Mn |
| Sep 30, 2020 | -4.31 Mn |
| Jun 30, 2020 | -7.28 Mn |